Customization: | Available |
---|---|
CAS No.: | 76095-16-4 |
Formula: | C24h32n2o9 |
Still deciding? Get samples of US$ 1/kg
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name | API Raw Material Powder CAS 76095-16-4 99% Enalapril maleate |
Appearance | White powder |
Molecular formula | C24h32n2o9 |
Molecular Weight | 492.525 |
Keywords | API Raw Material Enalapril maleate;Enalapril maleate Powder;Enalapril maleate |
24 months when properly stored | |
Storage | Keep in a cool, dry, dark location |
Enalapril maleate is used for All stages of essential hypertension; renal vascular hypertension; heart failure at all levels, for patients with symptomatic heart failure, this product is also suitable for improving survival, delaying the progression of symptomatic heart failure, reducing the cause of heart failure Hospitalization; prevention of symptomatic heart failure, prevention of coronary artery ischemic events in patients with asymptomatic left ventricular dysfunction, prevention of left ventricular dysfunction, this product is suitable for reducing the incidence of myocardial infarction.
What is Enalapril maleate?
Enalapril maleate is the second angiotensin converting enzyme inhibitor to reach the marketplace. Like captopril, the first entry in this area, enalapril is useful in the treatment of hypertension and congestive heart failure. It has a longer effective half-life than captopril, allowing once or twice-daily dosing, and appears to have a somewhat lower incidence of side effects.
The principle use of enalapril/enalaprilat in veterinary medicine at present is as a vasodilator in the treatment of heart failure. Recent studies have demonstrated that enalapril, particularly when used in conjunction with furosemide, does improve the quality of life in dogs with heart failure. It is not clear, however, whether it has any significant effect on survival times. It may also be of benefit in treating the effects associated with valvular heart disease (mitral regurgitation) and left to right shunts. It is being explored as adjunctive treatment in chronic renal failure and protein losing nephropathies.
Packing and delivering
Certification
FAQ